Oppenheimer & Co’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-60,683
| Closed | -$206K | – | 1415 |
|
|
2018
Q3 | $206K | Hold |
60,683
| – | – | 0.01% | 1214 |
|
|
2018
Q2 | $228K | Sell |
60,683
-3,555
| -6% | -$17.3K | 0.01% | 1172 |
|
|
2018
Q1 | $263K | Sell |
64,238
-400
| -0.6% | -$1.86K | 0.01% | 1114 |
|
|
2017
Q4 | $301K | Buy |
64,638
+900
| +1% | +$4.96K | 0.01% | 1053 |
|
|
2017
Q3 | $453K | Sell |
63,738
-6,483
| -9% | -$46.6K | 0.01% | 880 |
|
|
2017
Q2 | $508K | Buy |
70,221
+15,816
| +29% | +$98.8K | 0.01% | 827 |
|
|
2017
Q1 | $335K | Sell |
54,405
-15,111
| -22% | -$82.8K | 0.01% | 956 |
|
|
2016
Q4 | $407K | Buy |
69,516
+3,600
| +5% | +$19.7K | 0.01% | 878 |
|
|
2016
Q3 | $350K | Buy |
65,916
+3,600
| +6% | +$19.4K | 0.01% | 934 |
|
|
2016
Q2 | $412K | Buy |
62,316
+9,500
| +18% | +$53.1K | 0.01% | 854 |
|
|
2016
Q1 | $247K | Buy |
52,816
+500
| +1% | +$2K | 0.01% | 1018 |
|
|
2015
Q4 | $264K | Buy |
52,316
+11,350
| +28% | +$53.9K | 0.01% | 1004 |
|
|
2015
Q3 | $144K | Sell |
40,966
-68,424
| -63% | -$458K | ﹤0.01% | 1224 |
|
|
2015
Q2 | $1.09M | Sell |
109,390
-842
| -0.8% | -$9.03K | 0.03% | 592 |
|
|
2015
Q1 | $1.4M | Buy |
110,232
+8,051
| +8% | +$103K | 0.04% | 525 |
|
|
2014
Q4 | $1.45M | Sell |
102,181
-8,110
| -7% | -$126K | 0.04% | 498 |
|
|
2014
Q3 | $1.52M | Sell |
110,291
-32,816
| -23% | -$502K | 0.05% | 463 |
|
|
2014
Q2 | $2.2M | Buy |
143,107
+47,164
| +49% | +$669K | 0.07% | 351 |
|
|
2014
Q1 | $1.64M | Sell |
95,943
-19,524
| -17% | -$295K | 0.05% | 435 |
|
|
2013
Q4 | $1.5M | Sell |
115,467
-4,211
| -4% | -$50.3K | 0.05% | 429 |
|
|
2013
Q3 | $1.21M | Buy |
119,678
+53,503
| +81% | +$476K | 0.04% | 468 |
|
|
2013
Q2 | $494K | Buy |
+66,175
| New | +$517K | 0.02% | 722 |
|
Oppenheimer & Co's KERX Position: Q4 2018 in Review
Oppenheimer & Co sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 60,683 shares — an estimated $206K sold.
Oppenheimer & Co first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $2.2M in Q2 2014. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Oppenheimer & Co reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Oppenheimer & Co sold 60,683 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $206K.
- Oppenheimer & Co first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- Oppenheimer & Co's Keryx Biopharmaceuticals Inc position peaked at $2.2M in Q2 2014.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Oppenheimer & Co's 13F filing for Q4 2018, filed 29 Jan 2019.